In the current, study we sought to confirm tissue expression levels of the lysyl oxidases in SSc patients and preclinical fibrotic disease models, and to demonstrate the anti-fibrotic efficacy of PXS-5505 (via inhibition of collagen crosslinking) in preclinical fibrotic models resembling SSc. This evidence concerns the gene LOX and systemic sclerosis.